BOSTON (Reuters) - Two shots of the cancer drug Rituxan given two weeks apart slowed the progression of multiple sclerosis for nearly a year, researchers reported on Wednesday.
And Rituxan appears to be twice as effective as first-line treatments for MS, which reduce the number of relapses by about a third, the researchers said.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!